Abstract
The discovery of many new targets by chemical genetics has frequently exploited the fact that their biologically active chemical ligands were reactive and thus could covalently bind to their protein target(s). When experimental compounds or therapeutic agents with unidentified mechanisms of action do not contain reactive groups that can covalently label the putative site of molecular action, it may be possible to create a reactive photo-affinity probe if there is sufficient knowledge of the structure-activity relationship of the chemical series. Two specific examples are presented. These include the use of photo-affinity probes in the identification of the mechanism of action of synthetic oxazolidinones, a class of novel acting antibiotics and in the identification of a novel target for the insulin-sensitizing thiazolidinediones. Developments in photoaffinity labeling and combinatorial library design now imply that the parallel incorporation of photo-probes into screening library design could, at least in principle, greatly facilitate reverse pharmacological and chemical genetics approaches to protein target discovery.
Keywords: photo-affinity labeling, photoprobe, reverse pharmacology, oxazolidinone, thiazolidinedione, mitoneet
Combinatorial Chemistry & High Throughput Screening
Title: Photo-Affinity Labeling Strategies in Identifying the Protein Ligands of Bioactive Small Molecules: Examples of Targeted Synthesis of Drug Analog Photoprobes
Volume: 7 Issue: 7
Author(s): Jerry R. Colca and George G. Harrigan
Affiliation:
Keywords: photo-affinity labeling, photoprobe, reverse pharmacology, oxazolidinone, thiazolidinedione, mitoneet
Abstract: The discovery of many new targets by chemical genetics has frequently exploited the fact that their biologically active chemical ligands were reactive and thus could covalently bind to their protein target(s). When experimental compounds or therapeutic agents with unidentified mechanisms of action do not contain reactive groups that can covalently label the putative site of molecular action, it may be possible to create a reactive photo-affinity probe if there is sufficient knowledge of the structure-activity relationship of the chemical series. Two specific examples are presented. These include the use of photo-affinity probes in the identification of the mechanism of action of synthetic oxazolidinones, a class of novel acting antibiotics and in the identification of a novel target for the insulin-sensitizing thiazolidinediones. Developments in photoaffinity labeling and combinatorial library design now imply that the parallel incorporation of photo-probes into screening library design could, at least in principle, greatly facilitate reverse pharmacological and chemical genetics approaches to protein target discovery.
Export Options
About this article
Cite this article as:
Colca R. Jerry and Harrigan G. George, Photo-Affinity Labeling Strategies in Identifying the Protein Ligands of Bioactive Small Molecules: Examples of Targeted Synthesis of Drug Analog Photoprobes, Combinatorial Chemistry & High Throughput Screening 2004; 7 (7) . https://dx.doi.org/10.2174/1386207043328337
DOI https://dx.doi.org/10.2174/1386207043328337 |
Print ISSN 1386-2073 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5402 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pharmaceutical Strategies for Activating Sirtuins
Current Pharmaceutical Design Associations between Adiponectin Gene Variability, Proinflammatory and Angiogenetic Markers: Implications for Microvascular Disease Development in Type 2 Diabetes Mellitus?
Current Vascular Pharmacology Highly Selective MEK Inhibitors
Current Enzyme Inhibition Healing Effects of Curcumin Nanoparticles in Deep Tissue Injury Mouse Model
Current Drug Delivery Deficient Phagocytosis Among HIV-1 Infected Adults Over Time Even in HAART Setting
Current HIV Research Recombinant Factor VIIA, its Clinical Properties, and the Tissue Factor Pathway of Coagulation
Mini-Reviews in Medicinal Chemistry New Generation Calcium Channel Blockers in Hypertensive Treatment
Current Hypertension Reviews Pathomechanisms of Myocardial Dysfunction in Sepsis
Endocrine, Metabolic & Immune Disorders - Drug Targets Monoclonal Antibodies in Solid Tumours
Current Clinical Pharmacology Women in LOVe: Lacto-Ovo-Vegetarian Diet Rich in Omega-3 Improves Vasomotor Symptoms in Postmenopausal Women. An Exploratory Randomized Controlled Trial
Endocrine, Metabolic & Immune Disorders - Drug Targets Insulin-Like Growth Factor-1 and its Derivatives: Potential Pharmaceutical Application for Treating Neurological Conditions
Recent Patents on CNS Drug Discovery (Discontinued) Oxidative stress and Parkinson’s disease: New hopes in treatment with herbal antioxidants
Current Pharmaceutical Design A Comparative Study of Short Term Efficacy of Aripiprazole and Risperidone in Schizophrenia
Current Neuropharmacology Acute Gout: The Inflammasome
Current Rheumatology Reviews Acute Kidney Injury: Turning the Tide
Current Drug Targets The Anti-Inflammatory Potential of ACE2/Angiotensin-(1-7)/Mas Receptor Axis: Evidence from Basic and Clinical Research
Current Drug Targets Glyoxal Induced Transition of Transferrin to Aggregates: Spectroscopic, Microscopic and Molecular Docking Insight
Current Pharmaceutical Biotechnology Antitubercular Properties of Substituted Hydroxycyclohexadienones
Letters in Drug Design & Discovery Targeting the PI3K/Akt/mTOR Axis by Apigenin for Cancer Prevention
Anti-Cancer Agents in Medicinal Chemistry Functions of Ghrelin in Brain, Gut and Liver
CNS & Neurological Disorders - Drug Targets